Updates in the Journey for Disease-Modifying Therapies for Alzheimer Disease

Release Date: December 14, 2020
Expiration Date: December 14, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in Alzheimer disease, the most common cause of dementia among older adults. In this educational program, faculty discuss current and emerging biomarkers that can aid in earlier diagnosis. Current treatments that address symptoms will be reviewed. Pathophysiologic targets for agents in clinical trials are described, followed by presentation of data on second-generation immunotherapies. The program will conclude with practical approaches to manage comorbidities and improve quality of life for both patients and caregivers, along with the latest evidence for a healthy-brain lifestyle.

This educational activity is an archive of the live virtual symposium held on November 24, 2020.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Biogen.

Target Audience

This online educational activity is directed toward neurologists, primary care physicians, physician assistants, and nurses specializing in neurologic disorders.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Explain neurodegenerative alterations that are considered the hallmarks of AD versus different neurodegenerative disorders
• Implement screening and diagnostic protocols in clinical practice to ensure early detection of AD
• Analyze key data on new and emerging treatment options for AD to properly educate patients and impacted caregivers
• Construct team-based strategies to improve coordination of care for patients with AD

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Richard S. Isaacson, MD, FAAN
Director, Alzheimer’s Prevention Clinic
Associate Professor of Neurology
NewYork-Presbyterian Hospital/Weill Cornell Medicine
New York, NY

Disclosures: Richard S. Isaacson, MD, FAAN, has no relevant financial relationships with commercial interests.

Marc E. Agronin, MD
Senior Vice President, Behavioral Health
Chief Medical Officer, MIND Institute
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Miami, FL

Disclosures: Grant/Research Support: Biogen; Lilly, Roche, Alzheon, Sage Therapeutics, Johnson & Johnson; Consultant: Biogen, Lilly; Speakers’ Bureau: Biogen.

Sharon Cohen, MD, FRCPC
Neurologist and Medical Director
Toronto Memory Program
Toronto, Canada

Disclosures: Grant/Research Support: AbbVie, AgeneBio, Alector, Anavex Life Sciences, Biogen, Certification Commission for Healthcare Interpreters, Eisai, Janssen Pharmaceuticals, Lilly, RetiSpec, Vielight; Consultant: Alnylam Pharmaceuticals, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec; Content: investigational/unapproved: aducanumab, BAN2401, other Alzheimer disease investigational products.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.